BDX
Becton DickinsonNYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-05-08
As of May 8, 2026, BDX has a composite score of 16.5 and a signal label of "mild favorable." The score is influenced by a medium confidence level of 66.1 and a moderate risk label. Key drivers include macro factors related to labor, rates, growth, and inflation, with sector trends and guidance changes also impacting the outlook. The analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.18
- Bonus0.00
Why this rank
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $3.07 → $3.08 (+0.4% / 30d). 2 raised, 2 cut, 12 covering analysts.
0 upgrades, 0 downgrades / 30d, 3 maintained. 44% of analysts rate Buy.
3 PT revisions / 30d. Avg target 7.8% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
26 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Spin-off Biosciences and Diagnosticsgrowthwatchprovisional
11/6: “CEO: 'We remain on track to complete the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation.'”
Why this status
Stated in 3 of last 3 quarters. The spin-off of the Biosciences and Diagnostic Solutions business and its combination with Waters Corporation was expected to close in early 2026. This strategic move is part of BD's growth strategy to focus on New BD and enhance shareholder value. The trajectory is delivering as the transaction was expected to complete as planned.
- 2.Execute share repurchase programcapital allocationmixed36% progress
2/9: “BD expects to use $2 billion of the proceeds to repurchase BD common shares through an accelerated share repurchase program.”
Why this status
Stated in 2 of last 2 quarters. BD announced plans to use $2 billion from a cash distribution for share repurchases. The company had previously completed $750 million in share repurchases in FY25. The trajectory shows mixed progress, with the new $2 billion program announced but not yet executed.
- 3.Repay debt with cash distributioncapital allocationmixed36% progress
2/9: “BD expects to use $2 billion of the cash distribution for debt repayments.”
Why this status
Newly stated in 2026-Q1. BD announced its intention to use $2 billion from a cash distribution for debt repayment. This is a new capital allocation priority, and its execution will need to be tracked in future quarters.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 27%; 252d 25%.
Drawdown — Max 1y −22%. Bad day move −2%.
Beta to sector ETF (XLV) — 0.81 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 59/100, drawdown 57/100, beta 82/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Spin-off Biosciences and Diagnostics
GrowthNew since 2026-05-04Complete the spin-off of the Biosciences and Diagnostic Solutions business and combine it with Waters Corporation.
On track →WatchStated in 3 of last 3 quarters. The spin-off of the Biosciences and Diagnostic Solutions business and its combination with Waters Corporation was expected to close in early 2026. This strategic move is part of BD's growth strategy to focus on New BD and enhance shareholder value. The trajectory is delivering as the transaction was expected to complete as planned.
No scoreCEO/CFO:“CEO: 'We remain on track to complete the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation.'”Earnings callSource dated 2025-11-06Stated 3 of last 8 quartersFirst seen 2026-05-04provisionalShow history (3)
- 2026-Q1Earnings call
“Combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation expected to close today.”
- 2025-Q4Earnings call
“We remain on track to complete the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation.”
- 2025-Q3Earnings call
“We announced in July an agreement to combine BD’s Biosciences and Diagnostic Solutions business with Waters Corporation.”
- #2
Execute share repurchase program
Capital allocationNew since 2026-05-04Utilize $2 billion from cash distribution for share repurchases through an accelerated share repurchase program.
MixedStated in 2 of last 2 quarters. BD announced plans to use $2 billion from a cash distribution for share repurchases. The company had previously completed $750 million in share repurchases in FY25. The trajectory shows mixed progress, with the new $2 billion program announced but not yet executed.
36%CEO/CFO:“BD expects to use $2 billion of the proceeds to repurchase BD common shares through an accelerated share repurchase program.”Multiple sourcesSource dated 2026-02-09Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“BD expects to use $2 billion of the proceeds to repurchase BD common shares through an accelerated share repurchase program.”
- 2025-Q3Earnings call
“Expects to complete remaining $250 million of $1 billion share buyback commitment by the end of fiscal 2025.”
- #3
Repay debt with cash distribution
Capital allocationNew since 2026-05-04Use $2 billion from cash distribution for debt repayment.
MixedNewly stated in 2026-Q1. BD announced its intention to use $2 billion from a cash distribution for debt repayment. This is a new capital allocation priority, and its execution will need to be tracked in future quarters.
36%CEO/CFO:“BD expects to use $2 billion of the cash distribution for debt repayments.”Multiple sourcesSource dated 2026-02-09Stated 1 of last 8 quartersFirst seen 2026-05-04Show history (1)
- 2026-Q1Multiple sources
“BD expects to use $2 billion of the cash distribution for debt repayments.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
BDX Becton Dickinson | +17 | inexpensive | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-05-07)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-05-07)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-072d agoItem 5.02
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On October 15, 2025, the Company filed a Current Report on Form 8-K that reported that Vitor Roque, who previously served as the Company’s Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis, was appointed as the Company’s interim Chief Financial Officer, effective December 5, 2025. Effective May 7, 2026 (th…
executive changeneutralscore 77 - 2026-05-072d agoItem 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On May 7, 2026, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its second fiscal quarter ending March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”). Details regard…
earnings preannouncement—score 63 - 2026-04-021mo agoItem 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. As previously disclosed, on February 9, 2026, Becton, Dickinson and Company (“BD”) completed the spin-off of its Biosciences and Diagnostic Solutions business and combination of the business with Waters Corporation. In order to assist investors, BD has furnished as Exhibit 99.1 recast historical financial information, which reflects the presentation of BD's former Biosciences and Diagnostics Solutions business as discontinued operations to provid…
earnings preannouncementnegativescore 34 - 2026-04-0929d agoItem 5.02
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On April 6, 2026, Richard E. Byrd, Executive Vice President and President of the Interventional segment of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Mr. Byrd will remain in his role through June. BD intends to name a successor to Mr. Byrd prior to his retirement date.
executive changeneutralscore 29 - 2026-02-092mo agoItem 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 9, 2026, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its first fiscal quarter ending December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”). Details…
earnings preannouncementnegativescore 10
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.